yahoo.com
22-May-2008
By Gelu Sulugiuc COPENHAGEN, May 22 (Reuters) - Danish pharmaceutical group Lundbeck (LUN.CO: ) said on Thursday it had acquired the European rights to Myriad Genetics' Flurizan, an experimental Alzheimer's drug it hopes can become the company's next blockbuster. Lundbeck will pay Myriad (MYGN.O:...
[read full story]